Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLY03
- Development stage
- Preclinical
- Lead developer
- Neuraly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NLY03** is an orally active neuroprotective small molecule agent in early discovery/preclinical development by Neuraly for neurodegenerative diseases, primarily targeting stroke and Parkinson's disease. It modulates targets within the **parthanatos cascade**, a regulated form of necrosis involving PARP1 hyperactivation, AIF translocation, and neuronal death, to promote neuronal survival pathways. Currently in lead optimization, it represents Neuraly's third pipeline candidate following GLP-1R agonist NLY01 and kinase inhibitor NLY02, with a focus on blood-brain barrier penetration for central nervous system protection.
- Other names
- NLY-03NLY03NLY 03
02
Targets
Parthanatos cell death pathway
Beyond the preview
Go deeper on NLY03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLY03.